Managing depressive and anxiety disorders with escitalopram
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This article reviews escitalopram, the S-stereoisomer of the racemic compound citalopram, and a highly selective and potent member of the selective serotonin re-uptake inhibitor class of antidepressants. Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose. Similar to other members of the selective serotonin re-uptake inhibitor class, escitalopram (10-20 mg/day) is a well-tolerated and effective treatment of major depressive disorder. Although relatively few head-to-head comparative studies with other antidepressants have been published, pooled analyses of studies using citalopram as the active comparator suggest a modest advantage for the stereoisomer. This advantage, which is more apparent among patients with greater symptom levels, may be attributable to a greater than predicted potency compared with citalopram, presumably as a result of the greater effect of escitalopram at the allosteric binding site of the serotonin transporter. Results of two published studies versus venlafaxine also suggest better tolerability in the context of comparable efficacy. Escitalopram is also approved for the treatment of generalised anxiety disorder (in the US) and social anxiety disorder and panic disorder (in the EU). Pharmacoeconomic models suggest that the greater drug acquisition cost of this patent-protected compound may be offset by greater efficacy (relative to generic citalopram) and tolerability (compared with extended release venlafaxine).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 1×
“These advantages in ease of use and safety were not offset by a decrease in efficacy: meta-analyses of progressively larger numbers of randomised controlled trials (RCTs) have consistently documented that the SSRIs and TCAs have comparable, across the board efficacy [7-9].”
BackgroundFRESCO, D. M., COLES, M. E., HEIMBERG, R. G., LIEBOWITZ, M. R., HAMI, S., STEIN, M. B., & GOETZ, D. (2001) · Psychological Medicine · doi:10.1017/s0033291701004056 · Cited by 874 · cited 3×
“A secondary analysis indicated that the advantage of escitalopram 20 mg/day over paroxetine 20 mg/day was evident on five out of six subscales of the LSAS [64].”
BackgroundMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“In humans, escitalopram 10 mg results in ∼ 80% blockade of the serotonin transporter [24].”
BackgroundLepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Valuck, R. J., Libby, A. M., Sills, M. R., Giese, A. A., & Allen, R. R. (2004) · CNS Drugs · doi:10.2165/00023210-200418150-00006 · Cited by 182
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168 · cited 5×
“In the first trial [48], which was conducted in primary care clinics, 293 out-patients were randomly assigned to 8 weeks of double-blind therapy with venlafaxine (75 – 150 mg/day; mean dose: 95 mg/day) or escitalopram (10 – 20 mg/day; mean dose: 12 mg/day).”
BackgroundMethodResultInfluentialLader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115 · cited 2×
“[62] consisted of a 12-week period of open-label escitalopram therapy, followed by 24 weeks of double-blind continuation therapy with either active escitalopram or placebo.”
BackgroundMethod
Cited by
The Forced Swim Test as a Model of Depressive-like Behavior
Yankelevitch-Yahav, R., Franko, M., Huly, A., & Doron, R. (2015) · Journal of Visualized Experiments · doi:10.3791/52587 · Cited by 754
Escitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Comparative efficacy of escitalopram in the treatment of major depressive disorder
Lam, R., & Ali (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12531 · Cited by 33
“Escitalopram has been demonstrated in many placebocontrolled, randomized, controlled trials to be an efficacious antidepressant for MDD.(10,11) Moreover, some randomized controlled trials have shown evidence for the superior efficacy and tolerability of escitalopram compared with other SSRIs and other agents.”
BackgroundInfluential
Metadata
- Authors
- Thase, M. E.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2006-02-27
- Volume
- 7
- Issue
- 4
- Pages
- 429-440
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2012549547
- Cited by
- 37
- References
- 11
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.